Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (176)

2024

  1. Diagnóstico nosológico y de extensión. Factores pronósticos

    Oncología clínica (Arán Ediciones), pp. 59-71

  2. Epidemiología del cáncer. Factores de riesgo y carcinogénesis

    Oncología clínica (Arán Ediciones), pp. 25-42

  3. Tumores de origen desconocido

    Oncología clínica (Arán Ediciones), pp. 407-418

2023

  1. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

  2. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

  3. Multimodal Physical Exercise and Functional Rehabilitation Program in Oncological Patients with Cancer-Related Fatigue—A Randomized Clinical Trial

    International Journal of Environmental Research and Public Health, Vol. 20, Núm. 6

  4. Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

2022

  1. Acute esophageal necrosis induced by immune checkpoint inhibitors

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 3, pp. 182-183

  2. Cardiac magnetic resonance to detect different patterns of myocardial injury in patients receiving immune checkpoint inhibitors

    Revista Espanola de Cardiologia, Vol. 75, Núm. 3, pp. 266-269

  3. Epidemiological Study of Prostate Cancer in the Province of Salamanca (2006-2015)

    Archivos espanoles de urologia, Vol. 75, Núm. 7, pp. 630-637

  4. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  5. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020) (Clinical and Translational Oncology, (2021), 23, 5, (913-921), 10.1007/s12094-020-02533-1)

    Clinical and Translational Oncology

  2. Dopamine receptors and the kidney: An overview of health-and pharmacological-targeted implications

    Biomolecules, Vol. 11, Núm. 2, pp. 1-16

  3. Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors

    Life, Vol. 11, Núm. 12

  4. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

  5. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 764-772

  6. Multimodal physical exercise and functional rehabilitation program in oncological patients with asthenia. study protocol

    BMC Nursing, Vol. 20, Núm. 1

  7. Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies

    Journal of Clinical Medicine, Vol. 10, Núm. 9

  8. The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives

    Applied Sciences (Switzerland), Vol. 11, Núm. 18